Skip to main content
NHS National Services Scotland Home
FOI release

FOI – 2025-3226 Plasma products (HTML)

Published on 22 January 2026

Date received – 19 December 2025 | Date responded – 22 January 2026

Request

I would like to submit an FOI request for the number of vials used and patients treated for the following products (see table below) at your trust used in 2025 (total January to December), broken down by brand and size, if possible. If the full-year data is not yet available, you can inform me about the currently available data.

If not all products are available at your institution, you can just fill in the data that you have access to.

Product Manufacturer Size (Units/mg), Number of vials used (Jan 19-Dec 2025), Number of patients treated (Jan 19-Dec 2025)

  • Prothrombin Complex Concentrate (PCC), Beriplex CSL Behring 500IU 20ml
  • 1000IU 40ml
  • Octaplex Octapharma 500IU 20ml
  • 1000IU 40ml
  • Prothromplex Takeda 600IU 17ml
  • FEIBA Takeda 200IU 10ml
  • 500IU 20ml
  • 1000IU 40ml
  • Others (if any please specify) (if any please specify)

Reversal Agents

  • Ondexxya (andexanet alfa) Astrazeneca 5x 200 mg

  • Praxbind (Idaracizumab) Boehringer Ingelheim 2x 2.5 g

  • Fibrinogen Concentrate (FC)

  • RiaSTAP CSL Behring 1.0g

  • FibCLOT LFB 1.5g

  • Fibryga Octapharma 1.0g

  • Others (if any please specify) (if any please specify)

  • Fresh Frozen Plasma (FFP)

  • Fresh Frozen Plasma Blood banks

  • Octaplas Octapharma

  • Cryoprecipitate

  • Cryoprecipitate Blood banks

  • Labile Blood Products

  • Whole blood Blood banks

  • Red blood cells Blood banks

  • Platelets Blood banks

  • Factor XIII

  • Fibrogammin CSL Behring 250IU 4ml

  • 1250IU 20ml

Response

I refer to your freedom of information request that we received on 19 December 2025 requesting the following information:

We have now completed the search of our records and can provide you with the following information:

Under Section 17 of the Freedom of Information Scotland Act, 2002 (FOISA) an organisation does not have to provide the requested information if it does not hold that information. NHS National Services Scotland (NSS) cannot provide details regarding the number of patients treated as this level of detail is not held by us. What we can provide you with is the following appendices.

Appendix 1 – Plasma products January to December 2025. This appendix provides the number of vials used broken down by size, that were distributed to NHS Scotland Hospitals in 2025. This is for usage of Beriplex and Prothromplex only.

Appendix 2 – Further plasma products January to November 2025, provides the volumes of FIEBA, Fibrogammin p and RiaSTAP used (please note data for December 2025 is not yet available).

You may wish to contact the individual Health Boards (HBs) to obtain more information regarding the usage of these medicines. Addresses are as follows:

I trust you will find the information of assistance and if you require any further information, please do not hesitate to contact us.

If you are unhappy with any aspect of how we have dealt with your request, you can make representations to us asking us to review the handling of your request.

If you require any further information, please contact the Associate Director Governance and Board Services (Board Secretary) within 40 working days of the date of this correspondence.

Contact

Email: nss.foi@nhs.scot

Address

NHS National Services Scotland
Headquarters
Gyle Square
1 South Gyle Crescent
Edinburgh
EH12 9EB

If after a review you are still unhappy, you also have the right to apply to the Scottish Information Commissioner, who can be contacted at Kinburn Castle, St Andrews, Fife, KY16 9DS, or via their application form.

National Services Scotland (NSS) is committed to publishing all information released in response to Freedom of Information requests. You can view all FOI responses within our FOI Publications repository.

Contents